Real-World Durability of Aflibercept 8 mg and Faricimab in Initiators Versus Switchers: A Multicenter Retrospective Analysis - PubMed
a day ago
- #treatment durability
- #anti-VEGF therapy
- #retinal diseases
- Study evaluates real-world treatment durability and outcomes for aflibercept 8 mg and faricimab in initiators vs. switchers.
- Initiators showed better treatment intervals (10 weeks) than switchers (9 weeks), with early switchers outperforming late switchers.
- Faricimab initiators had superior durability and greater central subfield thickness (CST) reductions compared to other groups.
- Medicare coverage correlated with longer treatment durability than Medicare Advantage.
- Findings advocate for early initiation of these therapies, as step-therapy delays may worsen clinical outcomes.